Topotecan in Glioma Undergoing A Clinically-Indicated Surgical Resection
Status:
Terminated
Trial end date:
2018-11-19
Target enrollment:
Participant gender:
Summary
Topotecan is an FDA-approved drug when given by intravenous infection. The purpose of this
study is to determine if treatment with topotecan by an alternative method, direct delivery
into the part of the brain where the tumor has spread, is safe and well tolerated. The
Cleveland Multiport Catheter is a new, investigational device that will be used to deliver
topotecan into tumor-infiltrated brain. A second purpose of this study is to determine
whether the Cleveland Multiport Catheter can be used effectively and safely to deliver
topotecan into tumor-infiltrated brain. This study will also examine how tumors responds to
treatment with topotecan. This study will also look at the way topotecan is injected into
tumors-infiltrated brain. A small amount of contrast dye (called gadolinium DTPA) will be
added to topotecan before it is injected. Pictures will be taken of the brain with an MRI
machine. This will allow the investigators to see where in the tumor-infiltrated brain the
topotecan has been injected. This study will collect medical information before, during, and
after treatment in order to better understand hot to make this type of procedure accessible
to patients.